Delta opioid receptor
Delta opioid receptor (DOR), also known as δ-opioid receptor, is one of the four types of opioid receptors. The delta opioid receptor, along with the other opioid receptors, is a G protein-coupled receptor (GPCR) that plays a crucial role in modulating pain, mood, and addiction. The endogenous ligands for this receptor are enkephalins, which are peptides that are involved in regulating nociception in the body.
Structure[edit | edit source]
The delta opioid receptor is encoded by the OPRD1 gene in humans. Like other GPCRs, the DOR is characterized by its seven transmembrane alpha-helices. The receptor operates through the mechanism of signal transduction via G proteins, which, upon activation, initiate a cascade of cellular responses including inhibition of adenylate cyclase, reduction of cAMP levels, and modulation of ion channels.
Function[edit | edit source]
The primary function of the delta opioid receptor is in the modulation of pain and analgesia. Activation of DOR can lead to a decrease in the perception of pain. Additionally, delta opioid receptors have been implicated in various other physiological and pathological processes, including mood regulation, immune response, and the development of tolerance to opioids.
Delta opioid receptors are distributed throughout the central and peripheral nervous system but are less prevalent than mu-opioid receptors. Their specific roles and mechanisms in different tissues are an ongoing area of research.
Clinical Significance[edit | edit source]
The delta opioid receptor is a potential target for the development of new analgesics that could offer pain relief without the addictive properties and other adverse effects associated with traditional opioids that primarily target the mu-opioid receptor. Furthermore, research suggests that agonists of the delta opioid receptor may have antidepressant and anxiolytic effects, offering potential new avenues for the treatment of mood disorders.
Pharmacology[edit | edit source]
Several synthetic and natural ligands bind to the delta opioid receptor with varying affinities. These include peptides like enkephalins and non-peptide molecules. The development of selective delta opioid receptor agonists and antagonists is an area of active research, with the goal of finding compounds that can provide therapeutic benefits without the side effects associated with non-selective opioid receptor activation.
Research Directions[edit | edit source]
Research on the delta opioid receptor continues to explore its role in pain, mood regulation, neuroprotection, and addiction. Studies are investigating the receptor's signaling pathways, the development of DOR-selective ligands, and the potential therapeutic applications of modulating DOR activity.
See Also[edit | edit source]
This GPCR-related article is a stub. You can help WikiMD by expanding it.
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD